Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H23NO3 |
| Molecular Weight | 313.3915 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOc1ccccc1O[C@]([H])(c2ccccc2)[C@@]3([H])CNCCO3
InChI
InChIKey=CBQGYUDMJHNJBX-RTBURBONSA-N
InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m1/s1
| Molecular Formula | C19H23NO3 |
| Molecular Weight | 313.3915 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment:: description was created based on several sources, including:
https://www.drugs.com/uk/reboxetine-4mg-tablets-leaflet.html | https://www.ncbi.nlm.nih.gov/pubmed/11249515 | https://www.ncbi.nlm.nih.gov/pubmed/14647527
Curator's Comment:: description was created based on several sources, including:
https://www.drugs.com/uk/reboxetine-4mg-tablets-leaflet.html | https://www.ncbi.nlm.nih.gov/pubmed/11249515 | https://www.ncbi.nlm.nih.gov/pubmed/14647527
Reboxetine is a selective noradrenergic reuptake inhibitor that acts by binding to the norepinephrine (NE) transporter and blocking reuptake of extracellular NE back into terminals. This compound has low affinity for other transporters and receptors. Reboxetine is used in acute treatment of depressive illness / major depression. Very common side effects are: difficulties to sleep (insomnia); dizziness; dry mouth; constipation; nausea (feeling sick); sweating. Based on studies conducted primarily outside the US, the FDA granted a preliminary letter of approval in 1999. However, more recent clinical studies conducted in the US and Canada, prompted by the FDA, resulted in a letter of non-approval.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Noradrenalin reuptake |
8.0 nM [IC50] | ||
Target ID: Serotonin reuptake |
1.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | EDRONAX Approved UseReboxetine is indicated for the acute treatment of depressive illness/major depression and for maintaining the clinical improvement in patients initially responding to treatment. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. | 1995 Aug |
|
| Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. | 1997 Apr |
|
| Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril. | 2008 |
|
| Total Prolift System surgery for treatment posthysterectomy vaginal vault prolapse--do we treat both anatomy and function? | 2008 Dec |
|
| [Choice of a surgical treatment of genital prolapse in women]. | 2008 Nov-Dec |
|
| [Clinical study on concomitant surgery for stress urinary incontinence and pelvic organ prolapse]. | 2008 Oct 15 |
|
| [Occult stress incontinence identified by preoperative urodynamic study in women with severe pelvic organ prolapse]. | 2008 Sep |
|
| Implants in operative therapy in women with pelvic organ prolapse--two years of experience. | 2009 |
|
| Vaginal vault prolapse. | 2009 |
|
| Vaginal repair of cystocele with anterior wall mesh via transobturator route: efficacy and complications with up to 3-year followup. | 2009 |
|
| [Surgical treatment of female pelvic organ prolapse at the Clinic of Obstetrics and Gynecology, Hospital of Kaunas University of Medicine]. | 2009 |
|
| Psychopharmacology of ADHD in pediatrics: current advances and issues. | 2009 |
|
| The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression. | 2009 |
|
| Outcome of treatment of anterior vaginal wall prolapse and stress urinary incontinence with transobturator tension-free vaginal mesh (prolift) and concomitant tension-free vaginal tape-obturator. | 2009 |
|
| [Transvaginal repair of genital prolapse with prolift: a standardized surgery?]. | 2009 Apr |
|
| Perineal approach to vascular anatomy during transobturator cystocele repair. | 2009 Apr |
|
| [Transvaginal repair of genital prolapse with Prolift: evaluation of safety and learning curve]. | 2009 Feb |
|
| De novo stress incontinence and pelvic muscle symptoms after transvaginal mesh repair. | 2009 Jul |
|
| Changes in levator ani muscle after vaginal hysterectomy and prolapse repair using the Total Prolift procedure. | 2009 Jul |
|
| [Clinical observation on quality of life of two different operative methods of total pelvic floor reconstruction.]. | 2009 Nov |
|
| A serious complication following placement of posterior Prolift. | 2009 Nov |
|
| Anatomic outcomes of vaginal mesh procedure (Prolift) compared with uterosacral ligament suspension and abdominal sacrocolpopexy for pelvic organ prolapse: a Fellows' Pelvic Research Network study. | 2009 Nov |
|
| Synthetic graft use in vaginal prolapse surgery: objective and subjective outcomes. | 2009 Nov |
|
| Short term impact on female sexual function of pelvic floor reconstruction with the Prolift procedure. | 2009 Nov |
|
| Laparoscopic sacrohysteropexy and myomectomy for uterine prolapse: a case report and review of the literature. | 2009 Nov 3 |
|
| Trocar-guided total tension-free vaginal mesh repair of post-hysterectomy vaginal vault prolapse. | 2009 Oct |
|
| Laparoscopic apical mesh excision for deep dyspareunia caused by mesh banding in the vaginal apex. | 2009 Sep |
|
| [Changes in the length of implanted mesh after reconstructive surgery of the anterior vaginal wall]. | 2010 Apr |
|
| [Prolene mesh comparing with sacrospinal fixation in the treatment of genital prolapse in women. Prospective multicentre randomized study]. | 2010 Apr |
|
| [Correlation between stress urinary incontinence or urgency and anterior compartment defect before and after surgical treatment]. | 2010 Apr |
|
| Transvaginal mesh repair of anterior and posterior vaginal wall prolapse: a clinical and ultrasonographic study. | 2010 Apr |
|
| Successful management of depression with reboxetine in a patient who developed Parkinsonism related to paroxetine use. | 2010 Apr |
|
| Permeation of herbicidal dichlobenil from a Casoron formulation through nitrile gloves. | 2010 Feb |
|
| Midterm prospective evaluation of TVT-Secur reveals high failure rate. | 2010 Jul |
|
| Permeation of chlorothalonil through nitrile gloves: collection solvent effects in the closed-loop permeation method. | 2010 Jul 15 |
|
| One-year outcome of concurrent anterior and posterior transvaginal mesh surgery for treatment of advanced urogenital prolapse: case series. | 2010 Jul-Aug |
|
| Mid-term results of pelvic organ prolapse repair using a transvaginal mesh: the experience in Sherbooke, Quebec. | 2010 Jun |
|
| Anatomical and functional outcomes of posterior intravaginal slingplasty for the treatment of vaginal vault or uterine prolapse: a prospective, multicenter study. | 2010 Mar |
|
| Does trocar-guided tension-free vaginal mesh (Prolift) repair provoke prolapse of the unaffected compartments? | 2010 Mar |
|
| Optimal primary minimally invasive treatment for patients with stress urinary incontinence and symptomatic pelvic organ prolapse: tension free slings with colporrhaphy, or Prolift with the tension free midurethral sling? | 2010 May |
|
| [Postoperative pain after transvaginal repair of pelvic organ prolapse with or without mesh]. | 2010 Nov |
|
| Pelvic magnetic resonance imaging for assessment of the efficacy of the Prolift system for pelvic organ prolapse. | 2010 Nov |
|
| [Patent for medical device: from design to marketing (example of Prolift®)]. | 2010 Oct |
|
| Transurethral and suprapubic mesh resection after Prolift bladder perforation: a case report. | 2010 Oct |
|
| Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. | 2010 Oct 12 |
|
| Now or later...Does timing of a midurethral sling in relation to transvaginal prolapse repair affect continence outcomes at 1 year? | 2010 Sep |
|
| Vaginal hysterectomy at the time of transvaginal mesh placement. | 2010 Sep |
|
| [Transvaginal repair of genital prolapse using the Prolift technique: a prospective study]. | 2010 Sep |
|
| Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade. | 2011 |
|
| Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152). | 2011 Oct 13 |
Sample Use Guides
8 mg a day (one 4 mg tablet twice a day). The maximum daily dose should not exceed 12 mg.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 15:11:07 UTC 2021
by
admin
on
Sat Jun 26 15:11:07 UTC 2021
|
| Record UNII |
947S0YZ36I
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
656118
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
||
|
WHO-ATC |
N06AX18
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
||
|
WHO-VATC |
QN06AX18
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
||
|
NCI_THESAURUS |
C265
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
71620-89-8
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
5858
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
127151
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
DB00234
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
REBOXETINE
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
M9514
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | Merck Index | ||
|
CHEMBL14370
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
60842
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | RxNorm | ||
|
SUB15112MIG
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
C074679
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
C72838
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
98769-81-4
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
SUPERSEDED | |||
|
4808
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
71620-89-8
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
947S0YZ36I
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
2361
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
Reboxetine
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
7701
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Tmax | PHARMACOKINETIC |
|
|
|||
| Biological Half-life | PHARMACOKINETIC |
|
|
|||